Manual Patient Selection for GLP-1 Therapy: A Comprehensive Guide
Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes and obesity. These medications have been shown to not only improve glycemic control but also promote weight loss, lower blood pressure, and reduce the risk of major adverse cardiovascular events. However, the successful use of GLP-1 therapy depends on careful patient selection and medical management.
Understanding GLP-1 Therapy
GLP-1 agonists work by mimicking the action of the naturally occurring hormone glucagon-like peptide-1, which is released in response to food intake. This hormone helps to regulate blood sugar levels, slow gastric emptying, and promote feelings of fullness and satiety.
Manual Patient Selection for GLP-1 Therapy
The manual selection of patients for GLP-1 therapy is a critical step in ensuring the safe and effective use of these medications. The following criteria should be considered when selecting patients for GLP-1 therapy:
- Age: GLP-1 agonists are typically prescribed to adults aged 18 years and older.
- Body Mass Index (BMI): GLP-1 therapy is often recommended for patients with a BMI of 30 kg/m2 or higher, or those with a BMI of 27 kg/m2 or higher with at least one additional risk factor for diabetes or cardiovascular disease.
- Medical History: Patients with a history of pancreatitis, thyroid cancer, or multiple endocrine neoplasia type 1 (MEN 1) syndrome should not be prescribed GLP-1 agonists.
- Concomitant Medications: Patients taking medications that may interact with GLP-1 agonists, such as warfarin, should be carefully managed and monitored.
- Renal Function: Patients with severe renal impairment should be carefully evaluated before initiating GLP-1 therapy.
-p-1080.png "PDFLetter to 2023 WHO Expert Committee on the Selection & Use of Essential ...")
